全文获取类型
收费全文 | 1411篇 |
免费 | 85篇 |
国内免费 | 107篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 38篇 |
妇产科学 | 27篇 |
基础医学 | 223篇 |
口腔科学 | 48篇 |
临床医学 | 178篇 |
内科学 | 251篇 |
皮肤病学 | 14篇 |
神经病学 | 62篇 |
特种医学 | 120篇 |
外科学 | 280篇 |
综合类 | 51篇 |
预防医学 | 68篇 |
眼科学 | 13篇 |
药学 | 161篇 |
中国医学 | 1篇 |
肿瘤学 | 57篇 |
出版年
2021年 | 28篇 |
2020年 | 12篇 |
2019年 | 20篇 |
2018年 | 25篇 |
2017年 | 18篇 |
2016年 | 23篇 |
2015年 | 33篇 |
2014年 | 36篇 |
2013年 | 48篇 |
2012年 | 43篇 |
2011年 | 58篇 |
2010年 | 42篇 |
2009年 | 38篇 |
2008年 | 52篇 |
2007年 | 107篇 |
2006年 | 66篇 |
2005年 | 79篇 |
2004年 | 49篇 |
2003年 | 59篇 |
2002年 | 33篇 |
2001年 | 39篇 |
2000年 | 40篇 |
1999年 | 25篇 |
1998年 | 53篇 |
1997年 | 42篇 |
1996年 | 40篇 |
1995年 | 23篇 |
1994年 | 26篇 |
1993年 | 19篇 |
1992年 | 27篇 |
1991年 | 14篇 |
1990年 | 25篇 |
1989年 | 24篇 |
1988年 | 29篇 |
1987年 | 25篇 |
1986年 | 31篇 |
1985年 | 19篇 |
1984年 | 14篇 |
1983年 | 8篇 |
1982年 | 11篇 |
1980年 | 8篇 |
1979年 | 16篇 |
1978年 | 13篇 |
1977年 | 8篇 |
1976年 | 11篇 |
1975年 | 12篇 |
1974年 | 9篇 |
1973年 | 16篇 |
1972年 | 9篇 |
1971年 | 12篇 |
排序方式: 共有1603条查询结果,搜索用时 15 毫秒
1.
2.
Bromocriptine (0.5 mg/kg) and apomorphine (0.03 mg/kg) exert moderate aphrodisiac effect in sexually sluggish rats. This effect appears rapidly and reaches its peak within 24 h. Amphetamine (2 mg/kg) acts similarly but with a more rapid onset and offset of the effect. A single dose of (-)deprenyl, a selective inhibitor of MAO-B, exerts a much more potent effect in this test. 相似文献
3.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
4.
5.
6.
7.
8.
Calcineurin Inhibitor Withdrawal from Sirolimus-Based Therapy in Kidney Transplantation: A Systematic Review of Randomized Trials 总被引:4,自引:0,他引:4
Atul V. Mulay Naser Hussain Dean Fergusson Greg A. Knoll 《American journal of transplantation》2005,5(7):1748-1756
Calcineurin inhibitor (CNI) withdrawal has been used as a strategy to improve renal allograft function, however, it also carries risk of acute rejection. We conducted a systematic review of randomized trials that involved CNI withdrawal from a sirolimus-based immunosuppressive regimen. The search strategy yielded six trials (n = 1047 patients) reported in eight publications. CNI withdrawal from sirolimus-based therapy, was associated with an increased risk of acute rejection (risk difference, 6%; 95% CI 2-10%, p = 0.002) but a higher creatinine clearance (mean difference, 7.49 mL/min; 95% CI 5.08-9.89 mL/min, p < 0.00001) at 1 year compared to continued CNI and sirolimus therapy. Graft loss (relative risk, 0.87; 95% CI 0.46-1.64, p = 0.66) and death (relative risk, 0.88; CI 0.40-1.96, p = 0.76) were similar in both groups at 1 year. Hypertension was significantly reduced in the CNI withdrawal group (relative risk, 0.56; 95% CI 0.40-0.78, p = 0.0006). CNI withdrawal from sirolimus-based therapy is associated with an increased risk of acute rejection in the short term with a significant improvement in renal function and a reduction in hypertension. Longer follow-up is needed to determine if these changes will result in a significant improvement in patient and graft survival. 相似文献
9.
The reduction of methemoglobin levels by antioxidants 总被引:1,自引:0,他引:1
Preventing the oxidation of hemoglobin in solution is one of the major requirements for the successful production and long-term storage of hemoglobin-based blood substitutes. To this end we have studied the effects of antioxidants on the rate of methemoglobin formation and disappearance in solutions of human and bovine hemoglobin at 4 degrees C and 37 degrees C. Ascorbate and desferal (5 mM) were observed to act as prooxidants, increasing the rate of methemoglobin formation at 37 degrees C. Trehalose, mannitol, glucose, and EDTA (5 mM) had no significant effect. Glutathione and NADH (10 mM) were the most effective antioxidants tested, causing a significant decrease in the rate of methemoglobin formation at 37 degrees C for periods of up to 50 hours. The combination of these antioxidants in bovine hemoglobin at 4 degrees C resulted in the reduction of methemoglobin levels to nearly undetectable levels in approximately 150 hours. In addition, NADH and glutathione were found to reduce methemoglobin levels to 10% over a period of 100 hours in a sample of human hemoglobin that had been stored at 4 degrees C for one year and had 60% methemoglobin. These results suggest that the prevention and reversal of methemoglobin formation during the long-term storage of hemoglobin solutions and hemoglobin-based blood substitutes may now be possible. 相似文献
10.
BACKGROUND: The recent introduction of urea sensors for dialysis monitoring
has made possible new approaches to urea kinetic modelling. In this study
we show how the equilibrated postdialysis urea concentration (Ceq) and Kt/V
corrected for double-pool urea kinetics (Kt/Vdp) can be accurately
determined using an on-line sensor providing a continuous measure of blood
water urea. A modification of the Smye constant volume double-pool theory
led to the following equations for Ceq and Kt/Vdp [formula: see text] where
Cpre is the blood concentration measured at the start of dialysis, t is the
length of the dialysis session (in min) and S(ex) is the constant slope of
the blood urea logarithm concentration decline following development of the
intercompartmental urea concentration gradient in the first 30-60 min of
dialysis. METHODS: These equations were tested in 11 patients undergoing
165-240 min of paired filtration dialysis with continuous monitoring of
blood urea concentration. Cpre was determined as the plateau concentration
during a preliminary period of 15-20 min of slow isolated ultrafiltration.
S(ex) was accurately determined from linear regression applied to the urea
sensor data from the 80-min point to the end of dialysis. RESULTS: Ceq and
Kt/Vdp determined from the above equations compared closely to values
determined from 25-40 min of urea rebound monitoring with the urea sensor:
10.6 +/- 3.0 versus 10.8 +/- 2.7 mmol/l (mean +/- SD) for Ceq and 1.21 +/-
0.24 versus 1.18 +/- 0.20 for Kt/Vdp, compared to single-pool values of
Kt/V = 1.34 +/- 0.23. CONCLUSION: This technique may be readily programmed
into on-line urea monitors to provide current and extrapolated values of
Ceq and Kt/Vdp from about the first hour of dialysis.
相似文献